Pharmaceutical Polypeptide market

According to Transparency Market Research market reports, the global polypeptide drug market will reach nearly 20 billion US dollars in 2015, 23.7 billion US dollars in 2020, and a compound growth rate of about 2.8% in 2014-2020. Peptide drugs are mainly used to treat major diseases related to cancer and metabolic disorders, which have a very important global market. At present, there are more than 80 kinds of polypeptide drugs in the global drug market, 200-300 kinds of polypeptide drugs in clinical trials, 500-600 kinds in pre-clinical trials, and more polypeptide drugs in the laboratory research stage. It is foreseeable that more and more peptide drugs will be approved by FDA to enter the drug market in the future. Some of the existing peptide drugs already have a considerable consumer market. In terms of drug varieties, Gratel acetate still ranks first in the sales of polypeptide drugs in 2016, with sales exceeding $4 billion for many years, followed by liraglutide and growth hormone, with global sales exceeding $2 billion, followed by octreotide, leuprorelin, tripeptide, exenatide and gor, respectively. Sherilyn and so on.